Kathryn J Ruddy1, Hao Guo2, Emily L Baker3, Matthew J Goldstein4, Erin E Mullaney3, Lawrence N Shulman5, Ann H Partridge3,4. 1. Department of Oncology, Mayo Clinic, Rochester, Minnesota. 2. Department of biostatistics and computational biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 5. Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Previous research has demonstrated that cancer survivors often fail to receive recommended care and also undergo unnecessary care; this reduces care quality and increases costs. METHODS: This phase 2 trial randomized 100 stage 0 to IIIa breast cancer patients who had primary care providers within a large Massachusetts-based hospital network (with accessible online records) to either coordinated follow-up care (CC), which entailed atailored survivorship care plan (SCP) and patient navigator calls every 3 months, or standard care (SC), which did not include an SCP or patient navigation, for 1 year after the completion of their last chemotherapy, surgery, or radiation treatment. The primary endpoint was the frequency of redundant examinations (>1 breast/chest wall examination per patient within any 30-day period in the absence of a new breast or chest wall complaint) over the year of follow-up. The total number of non-plastic surgery visits in the year of follow-up was a secondary endpoint. RESULTS: Two patients (both on CC) were ineligible, and 2 patients (1 per arm) had a recurrence or died during follow-up; this left 96 for analysis (47 in the CC arm and 49 in the SC arm). Twenty-two of the 47 CC patients (47%; 95% confidence interval, 32%-62%) and 19 of the 49 SC patients (39%; 95% confidence interval, 25%-54%) had 1 or more redundant breast/chest wall examinations during the year. The median number of non-plastic surgery visits was 12 for CC patients and 8 for SC patients. CONCLUSIONS:Early-stage breast cancer patients visit health care providers very frequently during their first year of follow-up and often receive unnecessary breast/chest wall examinations. An SCP and patient navigator calls did not reduce this surrogate for redundant care. Cancer 2016;122:3546-3554.
RCT Entities:
BACKGROUND: Previous research has demonstrated that cancer survivors often fail to receive recommended care and also undergo unnecessary care; this reduces care quality and increases costs. METHODS: This phase 2 trial randomized 100 stage 0 to IIIa breast cancerpatients who had primary care providers within a large Massachusetts-based hospital network (with accessible online records) to either coordinated follow-up care (CC), which entailed a tailored survivorship care plan (SCP) and patient navigator calls every 3 months, or standard care (SC), which did not include an SCP or patient navigation, for 1 year after the completion of their last chemotherapy, surgery, or radiation treatment. The primary endpoint was the frequency of redundant examinations (>1 breast/chest wall examination per patient within any 30-day period in the absence of a new breast or chest wall complaint) over the year of follow-up. The total number of non-plastic surgery visits in the year of follow-up was a secondary endpoint. RESULTS: Two patients (both on CC) were ineligible, and 2 patients (1 per arm) had a recurrence or died during follow-up; this left 96 for analysis (47 in the CC arm and 49 in the SC arm). Twenty-two of the 47 CC patients (47%; 95% confidence interval, 32%-62%) and 19 of the 49 SC patients (39%; 95% confidence interval, 25%-54%) had 1 or more redundant breast/chest wall examinations during the year. The median number of non-plastic surgery visits was 12 for CC patients and 8 for SC patients. CONCLUSIONS: Early-stage breast cancerpatients visit health care providers very frequently during their first year of follow-up and often receive unnecessary breast/chest wall examinations. An SCP and patient navigator calls did not reduce this surrogate for redundant care. Cancer 2016;122:3546-3554.
Authors: Kathryn J Ruddy; Jeph Herrin; Lindsey Sangaralingham; Rachel A Freedman; Ahmedin Jemal; Tufia C Haddad; Summer V Allen; Tina Hieken; Judy C Boughey; Patricia A Ganz; Rachel D Havyer; Nilay D Shah Journal: J Natl Cancer Inst Date: 2020-01-01 Impact factor: 13.506
Authors: Sarah J Skuli; Jennifer Y Sheng; Elissa T Bantug; Nelli Zafman; Carol Riley; Jessica M Ruck; Katherine C Smith; Claire F Snyder; Karen L Smith; Vered Stearns; Antonio C Wolff Journal: Breast Cancer Res Treat Date: 2018-11-07 Impact factor: 4.872
Authors: Sarah A Birken; Alecia S Clary; Shampa Bernstein; Jamiyla Bolton; Miriam Tardif-Douglin; Deborah K Mayer; Allison M Deal; Sara R Jacobs Journal: J Oncol Pract Date: 2018-07-13 Impact factor: 3.840
Authors: Sarah A Birken; Robin Urquhart; Corrine Munoz-Plaza; Alexandra R Zizzi; Emily Haines; Angela Stover; Deborah K Mayer; Erin E Hahn Journal: J Cancer Surviv Date: 2018-03-23 Impact factor: 4.442
Authors: Rebecca E Hill; Claire E Wakefield; Richard J Cohn; Joanna E Fardell; Mary-Ellen E Brierley; Emily Kothe; Paul B Jacobsen; Kate Hetherington; Rebecca Mercieca-Bebber Journal: Oncologist Date: 2019-10-25
Authors: Rebecca E Hill; Claire E Wakefield; Richard J Cohn; Joanna E Fardell; Mary-Ellen E Brierley; Emily Kothe; Paul B Jacobsen; Kate Hetherington; Rebecca Mercieca-Bebber Journal: Oncologist Date: 2019-10-25
Authors: Beverley L Høeg; Pernille E Bidstrup; Randi V Karlsen; Anne Sofie Friberg; Vanna Albieri; Susanne O Dalton; Lena Saltbæk; Klaus Kaae Andersen; Trine Allerslev Horsboel; Christoffer Johansen Journal: Cochrane Database Syst Rev Date: 2019-11-21